Compare NVMI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVMI | EXEL |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 14.0B |
| IPO Year | 2001 | 2000 |
| Metric | NVMI | EXEL |
|---|---|---|
| Price | $450.16 | $55.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $431.88 | $46.50 |
| AVG Volume (30 Days) | 490.2K | ★ 2.5M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $20.94 | $13.61 |
| Revenue Next Year | $19.53 | $13.13 |
| P/E Ratio | ★ $56.79 | $69.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $232.73 | $33.76 |
| 52 Week High | $615.99 | $57.57 |
| Indicator | NVMI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 48.96 |
| Support Level | $415.57 | $40.53 |
| Resistance Level | $487.97 | $57.57 |
| Average True Range (ATR) | 20.54 | 1.32 |
| MACD | -1.26 | -0.33 |
| Stochastic Oscillator | 42.54 | 2.45 |
Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing. The company provides high-performance metrology solutions across the semiconductor fabrication lifecycle and develops differentiated inline metrology solutions deployed by a broad range of customers, including integrated circuit manufacturers. Its portfolio combines high-precision hardware and software, enabling customers to improve device performance, enhance yields, and accelerate time to market. Its products include Dimensional Metrology, Materials Metrology, Chemical Metrology, and Software Solutions. The company operates in China, Taiwan, R.O.C., the United States and other regions, with maximum revenue coming from China.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.